13 reports

Biosimilars in Immunology Report Code: GDHCHT## Published: February 2020 Healthcare TABLE OF CONTENTS (##/ ##) ##.

  • Therapy
  • India
  • United States
  • Market Size
  • Celltrion, Inc.

Biosimilars in Oncology Report Code: GDHCHT## Published: August 2018 Healthcare TABLE OF CONTENTS (##/ ##) ##.

  • Therapy
  • India
  • United States
  • Market Size
  • Celltrion, Inc.

Insulin glargine biosimilars are used in the treatment for Type ## and Type ## diabetes.

  • Biosimilar
  • Therapy
  • Amgen Inc.
  • Biocon Limited
  • Celltrion, Inc.
  • To be Completed by Therapy
  • 5. Market Access of New and Innovative Oncology Therapies in the 5EU, and Related Case Studies

Preface ##.

  • Cancer
  • Oncology
  • Pharmaceutical
  • Therapy
  • Celltrion, Inc.
  • MAB PIPELINE BY COMPANY AND THERAPY AREA
  • 6 MAB PIPELINE

While the majority of products were associated with only one therapy area and one indication within that therapy area, ##. ##% of products displayed a degree of versatility across therapy areas, with ## products being used across more than five different

  • Medical Biotechnology
  • Monoclonal Antibody
  • Therapy
  • AbbVie Inc.
  • Celltrion, Inc.
  • SOME RECENT DEVELPOMENTS IN MAB BIOSIMILARS MARKET
  • 4.4 MONOCLONAL ANTIBODY (MAB) BIOSIMILARS MARKET AND FORECAST

The product is a basal insulin, an important mainstay of treatment for people with type ## and type ## diabetes.

  • Biosimilar
  • Medical Biotechnology
  • Pharmaceutical
  • Therapy
  • Celltrion, Inc.
  • MM, MARKETED AND PIPELINE BIOSIMILARS FOR PSA, 2016
  • ENBREL SWOT ANALYSIS, 2015

Pharmacology & Therapeutics; ##(##): ##-##. & Therapy; ##(suppl ##): S##.

  • Biosimilar
  • Epidemiology
  • Therapy
  • Celltrion, Inc.
  • Pfizer Inc.
  • Global competitive landscape 2015

At least one clinical trial necessary.

  • Biosimilar
  • Oncology
  • Therapy
  • Biocon Limited
  • Celltrion, Inc.
  • Mundipharma Enters into Licensing Agreement with Celltrion Healthcare Hungary for Remsima
  • 05/18/2017: Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Blitzima (rituximab)

One-year data including adverse drug reactions, serious adverse events and infections were observed to be similar among all treatment groups.

  • Healthcare
  • Monoclonal Antibody
  • Pharmaceutical
  • Therapy
  • Celltrion, Inc.
  • Teva Pharma Enters into Distribution Agreement with Celltrion
  • Parent

GlobalData Celltrion Healthcare Co Ltd' s, deal volume increased from one pharmaceuticals & healthcare deal in 2016 to three pharmaceuticals & healthcare deals in 2017.

  • Healthcare
  • Medical Biotechnology
  • Pharmaceutical
  • Therapy
  • Celltrion, Inc.
  • PFIZER (& HOSPIRA)
  • NOVARTIS (& SANDOZ) - 3/3

Valor PR Jan ##, 2016 - the first patient was dosed in a phase ## clinical study of its lead product candidate, IGN##, a novel investigational treatment for non- Hodgkin lymphoma (NHL).

  • Biosimilar
  • Therapy
  • Biogen Idec Inc.
  • Boehringer Ingelheim GmbH
  • Celltrion, Inc.
  • PARTNER 1: SAFC, INC.
  • COMPANY INFORMATION: TARGET AND ACQUIRER

Partner ## Partner ## Partner ## Deal status Deal category Deal sub-category Date of announcement COMPANY INFORMATION: PARTNERS Company type PARTNER ##: SHENZHEN MAIN LUCK PHARMACEUTICALS INC Private ORChem Co., Ltd.

  • Healthcare
  • Pharmaceutical
  • Therapy
  • Company
  • Celltrion, Inc.
  • Celltrion, Inc. - Pipeline by Top 10 Indication, 2016
  • Celltrion, Inc., Key Information

Treatment with rituximab results in prompt B-cell destruction.

  • Biosimilar
  • Monoclonal Antibody
  • Therapy
  • Company Operations
  • Celltrion, Inc.